Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Johnson & Johnson's 2024 Fourth-Quarter and Full-Year Earnings Report Revealed

January 28, 2025
Johnson & Johnson (JNJ) has released its highly anticipated earnings report for the fourth quarter and full-year of 2024. The pharmaceutical giant exceeded expectations, beating quarterly estimates with strong revenue growth across all segments.
In the fourth quarter, JNJ reported a total revenue of $25.6 billion, reflecting a 7% increase compared to the same period last year. This growth was mainly driven by the company's pharmaceutical division, which saw a significant boost in sales of its blockbuster drugs. Johnson & Johnson's consumer health and medical devices segments also performed well, contributing to the overall positive results.

For the full-year 2024, JNJ reported a total revenue of $97.3 billion, marking a 6% increase from the previous year. The company's exceptional performance can be attributed to its diverse portfolio of innovative products and strong international presence.

One of the key highlights of the earnings report was the approval of SPRAVATO esketamine as the first and only monotherapy for adults with treatment-resistant depression in the United States. This groundbreaking achievement reinforces Johnson & Johnson's commitment to developing cutting-edge treatments for mental health conditions.

Investors and analysts have reacted positively to the impressive earnings report, with many considering JNJ as a stable investment option. However, as always, it is crucial to consult professionals for accurate predictions on the future movement of JNJ's stocks. Stocks Prognosis can provide expert insights and recommendations to ensure informed investment decisions.

Overall, Johnson & Johnson's 2024 fourth-quarter and full-year earnings report showcases the company's continued growth and innovation in the healthcare industry. With a strong financial performance and promising developments in drug discovery, JNJ remains a frontrunner in shaping the future of healthcare.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....

JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....

JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....

JNJFebruary 18, 2025Johnson & Johnson reportedly wants to sell Cerenovus for 1B  ~1 min.

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

REGNJanuary 1, 2025Regeneron Pharmaceuticals, Inc.: Groundbreaking Discoveries in Drug Development  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has made remarkable progress in the field of drug development, delighting its investors with a decent 89% return over the past five years....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: A Promising Future Ahead  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, with investors enjoying a decent 89% return over the past five years....

REGNMarch 15, 2025Regeneron Pharmaceuticals Inc.: A Promising Investment Opportunity  ~2 min.

Regeneron Pharmaceuticals Inc....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: Discoveries and Innovations Driving Growth  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, driving growth and attracting investors....